Your end-to-end CDMO partner
for your viral vector projects

We are a pure play CDMO, specialized in development and manufacturing of viral vectors.
From development to market, we provide GMP viral vectors, contributing to the success of our clients’ immunotherapies and gene therapy innovations.
Our European sites are GMP certified
AREAS OF
EXPERTISE
Vaccines

Vaccines

Oncolytic (Virotherapies)

Oncolytic (Virotherapies)

Other Immunotherapies

Other Immunotherapies

Gene therapy

We have been a pioneer in developing and producing viral vectors.

We are grounded in the Mérieux family’s legacy of biology and vaccine expertise since 1897.

As a pure CDMO player, we contribute to the success of your immunotherapy and gene therapy innovations.

OUR LATEST NEWS

OXFORD BIOMEDICA SIGNS AGREEMENT TO ACQUIRE ABL EUROPE FROM INSTITUT MERIEUX

By Gaelle Besomi / 4 December 2023
Today, Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL...
Read More

HOW TO CHOOSE THE RIGHT CDMO PARTNER

By Gaelle Besomi / 24 October 2023
CDMOs are an efficient alternative to the in-house development process. ABL’s sole focus is on product development and manufacturing, allowing...
Read More

KEY CMC CONSIDERATIONS FOR THE DEVELOPMENT OF YOUR VIRUS / VIRAL-VECTOR PROGRAMS

By Gaelle Besomi / 19 October 2023
In the highly competitive biotech industry, trust and credibility play a pivotal role in attracting investors and securing funding. A...
Read More

Services

We support our customers’ viral vector projects
from Preclinical, Phase I, Phase II, Phase III up to Commercial

Process design
Process feasibility
Upstream and/or downstream process development (PD) & process transfer
Assay development and qualification
Master and working cell or virus banks
Scale-up and engineering run(s) GMP aseptic fill
GMP bulk drug substance
GMP aseptic fill/finish
Analytical lot release testing
ICH stability testing
Chemistry,
manufacturing
and controls
support